(Q53090926)

English

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

author name string

Daniel J Landsburg

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Sunita D Nasta

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Jakub Svoboda

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Jennifer J D Morrissette

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Stephen J Schuster

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

language of work or name

0 references

publication date

25 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

166

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

369-374

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Double-hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

MYC/BCL2 double-hit high-grade B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12901

21 January 2018

Identifiers

10.1111/BJH.12901

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24761809

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53090926&oldid=1107973781"